230 related articles for article (PubMed ID: 30556300)
1. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
[TBL] [Abstract][Full Text] [Related]
2. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol.
Robinson PC; Dalbeth N; Donovan P
Arthritis Care Res (Hoboken); 2021 Oct; 73(10):1537-1543. PubMed ID: 32558298
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
[TBL] [Abstract][Full Text] [Related]
6. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Gandhi PK; Gentry WM; Ma Q; Bottorff MB
J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
Perez-Ruiz F; Díaz-Torné C; Carcedo D
J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
13. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
Meltzer M; Pizzi LT; Jutkowitz E
Evid Based Med; 2012 Aug; 17(4):105-8. PubMed ID: 22345034
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
[TBL] [Abstract][Full Text] [Related]
15. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
16. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
[TBL] [Abstract][Full Text] [Related]
18. A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
Hong Y; Chen X; Li Z; Zhang X; Zhou C; Wang Y; Wang G; Wu W; Zhou D; Feng Li H
Pharmacogenet Genomics; 2023 Feb; 33(2):24-34. PubMed ID: 36729770
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
20. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
